Transdermal Fluid Removal - a novel community-based and patient self-administered treatment for fluid overload in heart failure
Lead Participant:
RENEPHRA LIMITED
Abstract
"Many heart-failure patients suffer from excessive fluid accumulation, causing swelling and breathing problems. Some of these patients do not respond to treatment with water pills (diuretics). Such patients need frequent admission to hospital for intravenous diuretics and in extreme cases, dialysis. This is inconvenient for patients, sometimes has little effect and is very expensive.
This project aims to further develop a concept of a new medical device for the relief of fluid accumulation. The device will remove fluid directly from underneath the skin. The skin is pierced with tiny (micro) needles and a vacuum is used to draw-up the fluid into a drainage bag. The device will be used at home by patients and carers; therefore reducing the need for hospitalisation. It has been shown to be safe and does not cause pain.
The project aims to show the device is economically viable to be developed as treatment option for heart failure patients with excessive fluid accumulation.
To deliver this project successfully, we have a team with a very strong track record, expertise and credibility in all areas: patient and public engagement, clinical science, product design and development, regulatory and commercial."
This project aims to further develop a concept of a new medical device for the relief of fluid accumulation. The device will remove fluid directly from underneath the skin. The skin is pierced with tiny (micro) needles and a vacuum is used to draw-up the fluid into a drainage bag. The device will be used at home by patients and carers; therefore reducing the need for hospitalisation. It has been shown to be safe and does not cause pain.
The project aims to show the device is economically viable to be developed as treatment option for heart failure patients with excessive fluid accumulation.
To deliver this project successfully, we have a team with a very strong track record, expertise and credibility in all areas: patient and public engagement, clinical science, product design and development, regulatory and commercial."
Lead Participant | Project Cost | Grant Offer |
---|---|---|
RENEPHRA LIMITED | £102,435 | £ 71,705 |
  | ||
Participant |
||
CENTRAL MANCHESTER UNIVERSITY HOSPITALS NHS FOUNDATION TRUST | £18,432 | £ 18,432 |
INVENTURES CONSULTING LTD | ||
INNOVATE UK |
People |
ORCID iD |
Idalia Dawidowska (Project Manager) |